New cocktail of immune drugs and radiation shows promise against stomach cancer
NCT ID NCT03776487
First seen Nov 03, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with chemotherapy and radiation before surgery can help treat stomach cancer that is still removable. About 32 adults with early-stage stomach or gastroesophageal junction cancer will receive this combination. The main goal is to check safety and side effects, and also to see how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.